Nucleoside analogs plus ritonavir in stable antiretroviral therapy- experienced HIV-infected children: A randomized controlled trial

JAMA

Volumn 283, Issue 4, 2000, Pages 492-498

  Nachman, Sharon ^a   Stanley, Kenneth ^e   Yogev, Ram ^h   Pelton, Stephen ^f   Wiznia, Andrew ^b   Lee, Sophia ^e   Mofenson, Lynne ⁱ   Fiscus, Susan ^k   Rathore, Mobeen ^l   Jimenez, Eleanor ^m   Borkowsky, William ^c   Pitt, Jane ^d   Smith, Mary E ^j   Wells, Barbara ⁿ   McIntosh, Kenneth ^g  

^a STONY BROOK UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d Children's Hospital of Boston ^*  (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BOSTON MEDICAL CENTER   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h CHILDREN'S MEMORIAL HOSPITAL   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^m San Juan City Hospital   (Puerto Rico)

ⁿ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ANEMIA; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MIXTURE; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING;

EID: 17044454954     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.4.492     Document Type: Article

References (17)

1. Englund JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med. 1997;336:1704-1712.
2. McKinney RE Jr, Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. J Pediatr. 1998;133:500-508.
3. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MM WR Morb Mortal Wkly Rep. 1998; 47(RR-4):1-43.
4. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [published correction appears in: MMWR Morb Mortal Wkly Rep. 1998;47:619]. MMWR Morb Mortal Wkly Rep. 1998;47(RR-5):43-82.
5. Yogev R, Stanley K, Nachman S, et al. Virologic efficacy of ZDV + 3TC vs d4T + Ritonavir vs ZDV + 3TC + Ritonavir in stable antiretroviral experienced HIV-infected children (Pediatric ACTG trial 338). In: Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 28-October 1, 1997; Toronto, Ontario. Abstract LB-6.
6. Centers for Disease Control and Prevention. Revised classification system for HIV infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43(RR-12):1-10.
7. Gelman R, Cheng SC, Kidd P, Waxdal M, Kagan J. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping. Clin Immunol Immunopathol. 1993;66:150-162.
8. Dyer JR, Pilcher CD, Shepard R, Schock J, Eron JJ, Fiscus SA. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1999;37:447-449.
9. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol. 1996;34:2695-2701.
10. Brambilla D, Leung S, Lew J, et al. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1998;36:311-314.
11. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: John Wiley; 1973.
12. Lehmann E. Nonparametrics: Statistical Methods Based on Ranks. San Francisco, Calif: Holden-Day; 1975.
13. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984;40:819-825.
14. Pocock SJ. Clinical Trials: A Practical Approach. New York, NY: John Wiley; 1983.
15. Palumbo PE, Kwok S, Waters S, et al. Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr. 1995;126:592-595.
16. Notermans DW, Goudsmit J, Danner SA, de Wolf F, Perelson AS, Mittler J. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS. 1998;12:1483-1490.
17. Mueller BU, Nelson RP Jr, Sleasman J, et al. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection. Pediatrics. 1998;101(3 pt 1):335-343.